We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+37.1%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$622M
AUM Growth
+$195M
Cap. Flow
+$80.5M
Cap. Flow %
12.95%
Top 10 Hldgs %
55.49%
Holding
44
New
12
Increased
14
Reduced
4
Closed
6

Top Buys

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$20.9M
2
STRO icon
Sutro Biopharma
STRO
+$18.1M
3
NTRA icon
Natera
NTRA
+$13M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$11.6M
5
ETNB
89bio
ETNB
+$10.7M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$16.9M
2
CBAY
Cymabay Therapeutics
CBAY
+$14.4M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$12.7M
4
GPCR icon
Structure Therapeutics
GPCR
+$9.4M
5
VKTX icon
Viking Therapeutics
VKTX
+$7.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KALV
26
DELISTED
KalVista Pharmaceuticals
KALV
$9.02M 1.45%
+760,722
New +$10.1M
RVMD icon
27
Revolution Medicines
RVMD
$44.6B
$8.81M 1.42%
273,217
-191
-0.1% -$5.66K
VERV
28
DELISTED
Verve Therapeutics
VERV
$8.47M 1.36%
638,163
– –
FOLD
29
DELISTED
Amicus Therapeutics
FOLD
$8.47M 1.36%
718,970
+3,087
+0.4% +$39.5K
AKRO
30
DELISTED
Akero Therapeutics
AKRO
$8.41M 1.35%
+332,924
New +$8M
ADAP
31
DELISTED
Adaptimmune Therapeutics
ADAP
$8.05M 1.29%
5,095,912
– –
EWTX icon
32
Edgewise Therapeutics
EWTX
$4.64B
$8.05M 1.29%
+441,259
New +$7.01M
RPTX
33
DELISTED
Repare Therapeutics
RPTX
$7.72M 1.24%
1,639,849
– –
RLAY icon
34
Relay Therapeutics
RLAY
$4.11B
$6.91M 1.11%
832,017
– –
IRON icon
35
Disc Medicine
IRON
$3.07B
$6.9M 1.11%
110,779
+60,779
+122% +$3.94M
TRVI icon
36
Trevi Therapeutics
TRVI
$2.39B
$4.63M 0.74%
+1,340,960
New +$2.99M
IMTX icon
37
Immatics
IMTX
$1.44B
$4.15M 0.67%
+395,237
New +$4.61M
CMPX icon
38
Compass Therapeutics
CMPX
$432M
$3.9M 0.63%
+1,971,402
New +$3.41M
GPCR icon
39
Structure Therapeutics
GPCR
$3.38B
– –
-230,696
Closed -$9.4M
INZY
40
DELISTED
Inozyme Pharma
INZY
– –
-323,813
Closed -$1.38M
PHAT icon
41
Phathom Pharmaceuticals
PHAT
$743M
– –
-70,000
Closed -$639K
CBAY
42
DELISTED
Cymabay Therapeutics
CBAY
– –
-611,181
Closed -$14.4M
KRTX
43
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
– –
-53,279
Closed -$16.9M
HARP
44
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-319,670
Closed -$3.63M
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q1 2024 Portfolio in Review

As of Q1 2024, MPM BioImpact held 44 positions worth $622M, up 46% from $427M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

MPM BioImpact deployed $80.5M of net new capital in Q1 2024, opening 12 new positions and adding to 14 existing holdings. Its largest new stake was Zentalis Pharmaceuticals: 1,516,183 shares worth $23.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Iovance Biotherapeutics, an estimated $12.7M trimmed.

  • MPM BioImpact's largest Q1 2024 buy was Zentalis Pharmaceuticals: 1,516,183 shares worth $23.9M.
  • MPM BioImpact added most to Viridian Therapeutics in Q1 2024, an estimated $9.96M increase.
  • MPM BioImpact's biggest Q1 2024 reduction was Iovance Biotherapeutics, cutting an estimated $12.7M.
  • MPM BioImpact fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $16.9M.
  • MPM BioImpact's ten largest holdings make up 55% of its $622M portfolio in Q1 2024.
  • MPM BioImpact opened 12 new positions and closed 6 in Q1 2024.
  • MPM BioImpact's portfolio value rose 46% quarter-over-quarter to $622M.

Based on MPM BioImpact's 13F filing for Q1 2024, filed 15 May 2024.